Clemastine Treatment in Individuals With Williams Syndrome

Status Recruiting

Clinical Trial Summary

This study explores the neurobiological etiology of Williams syndrome and potential therapeutic targets for associated social, motor, and cognitive abnormalities. The main translational objective will be to test the effectiveness of Clemasntine on neurocognitive and other associated abnormalities in individuals with Williams syndrome.

Clinical Trial Description

The overarching aim of the research proposed is to examine the safty of Clemastine use for individuals with Williams syndrome. Further, we wish to examine the relationship between Clemastine treatment and cognitive, motor and behavioral deficits in individuals with Williams syndrome. This study is an open-label study with a blinded randomize withdrawal. Each participant will go through a baseline evaluation (see study outcomes) and will be treated with the FDA approved drug Clemastine, in an age dependent dose (dosage table below). After a substantial improvement will be noticed, the participants will be divided into 2 groups, in a randomized, double-blind, placebo-control study design. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06087757
Study type	Interventional
Source	Sheba Medical Center
Contact
Status	Recruiting
Phase	Phase 3
Start date	January 2024
Completion date	December 2025

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00004351` - Study of Phenotype and Genotype Correlations in Patients With Contiguous Gene Deletion Syndromes	N/A
Completed	`NCT03758651` - Williams Syndrome Strength, Hormones, Activity & Adiposity, DNA Programming, Eating Study
Enrolling by invitation	`NCT03836300` - Parent-Infant Inter(X)Action Intervention (PIXI)	N/A
Completed	`NCT02212314` - Response Inhibition Training for Children With Williams Syndrome	N/A
Recruiting	`NCT00768820` - The Psychiatric and Cognitive Phenotypes in Velocardiofacial Syndrome	Phase 4
Recruiting	`NCT04610424` - Cooperative Parent Mediated Therapy in Children With Fragile X Syndrome and Williams Syndrome	N/A
Recruiting	`NCT02706639` - Williams Syndrome (WS) and Supravalvar Aortic Stenosis (SVAS) DNA and Tissue Bank
Completed	`NCT02692846` - WS-SAVE Study (Williams Syndrome Skin and Vessel Elasticity Study)
Recruiting	`NCT06315699` - Clemastine Fumarate in the Treatment of Neurodevelopmental Delays in Williams Syndrome	Phase 3
Recruiting	`NCT01793168` - Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Recruiting	`NCT01132885` - Defining the Brain Phenotype of Children With Williams Syndrome
Enrolling by invitation	`NCT05430763` - Motor Deficits and Signal Conduction in Individuals With Williams Syndrome
Completed	`NCT01864304` - Fat Distribution and Glucose Metabolism in Williams Syndrome	N/A
Recruiting	`NCT02840448` - Impact of Elastin Mediated Vascular Stiffness on End Organs
Recruiting	`NCT03827525` - Cognitive and Behavioral Therapy of Anxiety in Williams Syndrome
Completed	`NCT04807517` - Buspirone Treatment of Anxiety in Williams Syndrome	Phase 4
Completed	`NCT00013962` - Vitamin D Metabolism and the Williams Syndrome	N/A